English

Aratana Therapeutics, Inc.

EDGAR

PETX Quarterly report (10-Q) · filed 2019-05-09

113 filing records in this dataset, filed from 2013-03-20 to 2019-05-09. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

7.36 million Unit12

2019 Q1 · Unit12

Exact inputs and evidence

Revenue: 7360000 Unit12 Source

Operating margin

-94.59%

2019 Q1 · %

Exact inputs and evidence

Operating Income: -6962000 Unit12 Source
Revenue: 7360000 Unit12 Source

Operating cash flow

-5.49 million Unit12

2019 Q1 · Unit12

Exact inputs and evidence

Operating Cash Flow: -5491000 Unit12 Source

Cash and cash equivalents: 36.6 million Unit12 2019-03-31 Source
Exact value

36561000 Unit12
Long-term debt including current maturities: 36.5 million Unit12 2017-12-31 Source
Exact value

36500000 Unit12
Shares outstanding: 48.3 million Unit1 2019-03-31 Source
Exact value

48347297 Unit1

Reported share-count change

5.03% · 2.31 million Unit1

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

46033850 Unit1 · 2018-03-31· Source
48347297 Unit1 · 2019-03-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

38.7 million Unit12

2018-04-01 – 2019-03-31

Exact inputs and evidence

Revenue: 4908000 Unit12 · 2018-04-01 – 2018-06-30 Source
Revenue: 21555000 Unit12 · 2018-07-01 – 2018-09-30 Source
Revenue: 4906000 Unit12 · 2018-10-01 – 2018-12-31 Source
Revenue: 7360000 Unit12 · 2019-01-01 – 2019-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2019-05-09.

Financial data available through: 2018-12-31.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2018-12-31
Operating income: 7 of 11 periods available· newest 2018-12-31
Net income: 7 of 11 periods available· newest 2018-12-31
Operating cash flow: 7 of 11 periods available· newest 2018-12-31
Capital expenditure: 6 of 11 periods available· newest 2017-12-31
Total assets: 6 of 11 periods available· newest 2018-12-31
Total liabilities: 6 of 11 periods available· newest 2018-12-31
Current assets: 6 of 11 periods available· newest 2018-12-31
Current liabilities: 6 of 11 periods available· newest 2018-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2018-12-31
Long-term debt including current maturities: 4 of 11 periods available· newest 2017-12-31
Shares outstanding: 6 of 11 periods available· newest 2018-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+38.5%

Prior period

Unit12 25.57 million

2017-01-01 – 2017-12-31
Current period

Unit12 35.41 million

2018-01-01 – 2018-12-31

Exact inputs and evidence

35412000 − 25573000 = 9839000 Unit12

25573000 Unit12 · 2017-01-01 – 2017-12-31
Inspect prior input Prior source
35412000 Unit12 · 2018-01-01 – 2018-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Aratana Therapeutics, Inc. · 2018-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Year-over-year change in Revenue: 9839000 Unit12 Concept: fundies:Revenue Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 35412000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919019000018/petx-20181231.xml#1433721 Filing: 000150919019000018 Input fundies:Revenue: 25573000 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919019000018/petx-20181231.xml#1429039 Filing: 000150919019000018
The citation records this snapshot. The page link may show a newer release later.
Net income
+Unit12 32.79 million

Prior period

−Unit12 47.51 million

2017-01-01 – 2017-12-31
Current period

−Unit12 14.72 million

2018-01-01 – 2018-12-31

Exact inputs and evidence

-14722000 − -47510000 = 32788000 Unit12

-47510000 Unit12 · 2017-01-01 – 2017-12-31
Inspect prior input Prior source
-14722000 Unit12 · 2018-01-01 – 2018-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Aratana Therapeutics, Inc. · 2018-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Year-over-year change in Net income: 32788000 Unit12 Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -14722000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919019000018/petx-20181231.xml#1213223 Filing: 000150919019000018 Input fundies:NetIncome: -47510000 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919019000018/petx-20181231.xml#1212035 Filing: 000150919019000018
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+Unit12 26.92 million

Prior period

−Unit12 38.19 million

2017-01-01 – 2017-12-31
Current period

−Unit12 11.26 million

2018-01-01 – 2018-12-31

Exact inputs and evidence

-11261000 − -38185000 = 26924000 Unit12

-38185000 Unit12 · 2017-01-01 – 2017-12-31
Inspect prior input Prior source
-11261000 Unit12 · 2018-01-01 – 2018-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Aratana Therapeutics, Inc. · 2018-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Year-over-year change in Operating cash flow: 26924000 Unit12 Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -11261000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919019000018/petx-20181231.xml#1211313 Filing: 000150919019000018 Input fundies:OperatingCashFlow: -38185000 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919019000018/petx-20181231.xml#1211106 Filing: 000150919019000018
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2018 2018-01-01 – 2018-12-31

Revenue Unit12 35.41 million 100% of revenue
Cost of revenue Unit12 6.78 million 19% of revenue
Operating expenses Unit12 35.64 million 101% of revenue
Other operating costs Derived Unit12 4.88 million 14% of revenue
Operating income −Unit12 11.89 million −34% of revenue
Tax, interest and other Derived Unit12 2.83 million 8% of revenue
Net income −Unit12 14.72 million −42% of revenue

Cash

Operating cash flow −Unit12 11.26 million −32% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2013 Operating loss: operating costs were 16,182% of revenue.
2014 Operating loss: operating costs were 5,525% of revenue.
2015 Operating loss: operating costs were 13,300% of revenue.
2016 Operating loss: operating costs were 180% of revenue.
2017 Operating loss: operating costs were 274% of revenue.
2018 Operating loss: operating costs were 134% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2013 2013-01-01 – 2013-12-31	123000	19904000 Derived	-19781000	-12843000 Derived	-6938000	-16245000 Derived	Source 2013-01-01 – 2013-12-31: 123000 Unit12 Inspect Revenue Open source 2013-01-01 – 2013-12-31: -19781000 Unit12 Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -6938000 Unit12 Inspect Net Income Open source 2013-01-01 – 2013-12-31: -16151000 Unit12 Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 94000 Unit12 Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	767000	42376000 Derived	-41609000	-2793000 Derived	-38816000	-32659000 Derived	Source 2014-01-01 – 2014-12-31: 767000 Unit12 Inspect Revenue Open source 2014-01-01 – 2014-12-31: -41609000 Unit12 Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -38816000 Unit12 Inspect Net Income Open source 2014-01-01 – 2014-12-31: -32188000 Unit12 Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 471000 Unit12 Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	678000	90174000 Derived	-89496000	-5442000 Derived	-84054000	-40740000 Derived	Source 2015-01-01 – 2015-12-31: 678000 Unit12 Inspect Revenue Open source 2015-01-01 – 2015-12-31: -89496000 Unit12 Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -84054000 Unit12 Inspect Net Income Open source 2015-01-01 – 2015-12-31: -38495000 Unit12 Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 2245000 Unit12 Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	38551000	69370000 Derived	-30819000	2756000 Derived	-33575000	-11395000 Derived	Source 2016-01-01 – 2016-12-31: 38551000 Unit12 Inspect Revenue Open source 2016-01-01 – 2016-12-31: -30819000 Unit12 Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -33575000 Unit12 Inspect Net Income Open source 2016-01-01 – 2016-12-31: -11323000 Unit12 Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 72000 Unit12 Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	25573000	70029000 Derived	-44456000	3054000 Derived	-47510000	-38186000 Derived	Source 2017-01-01 – 2017-12-31: 25573000 Unit12 Inspect Revenue Open source 2017-01-01 – 2017-12-31: -44456000 Unit12 Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -47510000 Unit12 Inspect Net Income Open source 2017-01-01 – 2017-12-31: -38185000 Unit12 Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 1000 Unit12 Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	35412000	47300000 Derived	-11888000	2834000 Derived	-14722000	Unavailable	Source 2018-01-01 – 2018-12-31: 35412000 Unit12 Inspect Revenue Open source 2018-01-01 – 2018-12-31: -11888000 Unit12 Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -14722000 Unit12 Inspect Net Income Open source 2018-01-01 – 2018-12-31: -11261000 Unit12 Inspect Operating Cash Flow Open source

Amounts are exact, in Unit12.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit12 35.4M 2018

Values and sources

Revenue values and source evidence
Period	Series	Value(Unit12)	Source evidence
20132013-12-31	Revenue	123000	Revenue: 123000 Open source
20142014-12-31	Revenue	767000	Revenue: 767000 Open source
20152015-12-31	Revenue	678000	Revenue: 678000 Open source
20162016-12-31	Revenue	38551000	Revenue: 38551000 Open source
20172017-12-31	Revenue	25573000	Revenue: 25573000 Open source
20182018-12-31	Revenue	35412000	Revenue: 35412000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

38.5% 2018

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Year over year	No prior comparable period	Revenue: 123000 Open source
20142014-12-31	Year over year	523.6%	Revenue: 767000 Open source Revenue: 123000 Open source
20152015-12-31	Year over year	-11.6%	Revenue: 678000 Open source Revenue: 767000 Open source
20162016-12-31	Year over year	5,586%	Revenue: 38551000 Open source Revenue: 678000 Open source
20172017-12-31	Year over year	-33.7%	Revenue: 25573000 Open source Revenue: 38551000 Open source
20182018-12-31	Year over year	38.5%	Revenue: 35412000 Open source Revenue: 25573000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -33.6% 2018

Net margin -41.6% 2018

Free cash flow margin -149.3% 2017

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Operating margin	-16,082.1%	Operating Income: -19781000 Open source Revenue: 123000 Open source
20142014-12-31	Operating margin	-5,424.9%	Operating Income: -41609000 Open source Revenue: 767000 Open source
20152015-12-31	Operating margin	-13,200%	Operating Income: -89496000 Open source Revenue: 678000 Open source
20162016-12-31	Operating margin	-79.9%	Operating Income: -30819000 Open source Revenue: 38551000 Open source
20172017-12-31	Operating margin	-173.8%	Operating Income: -44456000 Open source Revenue: 25573000 Open source
20182018-12-31	Operating margin	-33.6%	Operating Income: -11888000 Open source Revenue: 35412000 Open source
20132013-12-31	Net margin	-5,640.7%	Net Income: -6938000 Open source Revenue: 123000 Open source
20142014-12-31	Net margin	-5,060.8%	Net Income: -38816000 Open source Revenue: 767000 Open source
20152015-12-31	Net margin	-12,397.3%	Net Income: -84054000 Open source Revenue: 678000 Open source
20162016-12-31	Net margin	-87.1%	Net Income: -33575000 Open source Revenue: 38551000 Open source
20172017-12-31	Net margin	-185.8%	Net Income: -47510000 Open source Revenue: 25573000 Open source
20182018-12-31	Net margin	-41.6%	Net Income: -14722000 Open source Revenue: 35412000 Open source
20132013-12-31	Free cash flow margin	-13,207.3%	Revenue: 123000 Open source Operating Cash Flow: -16151000 Open source Capital Expenditure: 94000 Open source
20142014-12-31	Free cash flow margin	-4,258%	Revenue: 767000 Open source Operating Cash Flow: -32188000 Open source Capital Expenditure: 471000 Open source
20152015-12-31	Free cash flow margin	-6,008.8%	Revenue: 678000 Open source Operating Cash Flow: -38495000 Open source Capital Expenditure: 2245000 Open source
20162016-12-31	Free cash flow margin	-29.6%	Revenue: 38551000 Open source Operating Cash Flow: -11323000 Open source Capital Expenditure: 72000 Open source
20172017-12-31	Free cash flow margin	-149.3%	Revenue: 25573000 Open source Operating Cash Flow: -38185000 Open source Capital Expenditure: 1000 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 35412000 Open source Operating Cash Flow: -11261000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Unit12 -11.3M 2018

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(Unit12)	Source evidence
20132013-12-31	Operating cash flow	-16151000	Operating Cash Flow: -16151000 Open source
20142014-12-31	Operating cash flow	-32188000	Operating Cash Flow: -32188000 Open source
20152015-12-31	Operating cash flow	-38495000	Operating Cash Flow: -38495000 Open source
20162016-12-31	Operating cash flow	-11323000	Operating Cash Flow: -11323000 Open source
20172017-12-31	Operating cash flow	-38185000	Operating Cash Flow: -38185000 Open source
20182018-12-31	Operating cash flow	-11261000	Operating Cash Flow: -11261000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Unit12 -38.2M 2017

Values and sources

Free cash flow values and source evidence
Period	Series	Value(Unit12)	Source evidence
20132013-12-31	Free cash flow	-16245000	Operating Cash Flow: -16151000 Open source Capital Expenditure: 94000 Open source
20142014-12-31	Free cash flow	-32659000	Operating Cash Flow: -32188000 Open source Capital Expenditure: 471000 Open source
20152015-12-31	Free cash flow	-40740000	Operating Cash Flow: -38495000 Open source Capital Expenditure: 2245000 Open source
20162016-12-31	Free cash flow	-11395000	Operating Cash Flow: -11323000 Open source Capital Expenditure: 72000 Open source
20172017-12-31	Free cash flow	-38186000	Operating Cash Flow: -38185000 Open source Capital Expenditure: 1000 Open source
20182018-12-31	Free cash flow	Unavailable	Operating Cash Flow: -11261000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

5.3% 2018

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Liabilities / assets	25.8%	Total Liabilities: 28953000 Open source Total Assets: 112343000 Open source
20142014-12-31	Liabilities / assets	12.5%	Total Liabilities: 26071000 Open source Total Assets: 207903000 Open source
20152015-12-31	Liabilities / assets	30.9%	Total Liabilities: 45516000 Open source Total Assets: 147066000 Open source
20162016-12-31	Liabilities / assets	40.3%	Total Liabilities: 61003000 Open source Total Assets: 151406000 Open source
20172017-12-31	Liabilities / assets	40.7%	Total Liabilities: 55058000 Open source Total Assets: 135192000 Open source
20182018-12-31	Liabilities / assets	5.3%	Total Liabilities: 5614000 Open source Total Assets: 106436000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

10.46× 2018

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Current assets / current liabilities	2.85×	Current Assets: 48208000 Open source Current Liabilities: 16901000 Open source
20142014-12-31	Current assets / current liabilities	10.55×	Current Assets: 99909000 Open source Current Liabilities: 9468000 Open source
20152015-12-31	Current assets / current liabilities	15.66×	Current Assets: 89019000 Open source Current Liabilities: 5684000 Open source
20162016-12-31	Current assets / current liabilities	2.93×	Current Assets: 101542000 Open source Current Liabilities: 34688000 Open source
20172017-12-31	Current assets / current liabilities	2.4×	Current Assets: 85239000 Open source Current Liabilities: 35496000 Open source
20182018-12-31	Current assets / current liabilities	10.46×	Current Assets: 58127000 Open source Current Liabilities: 5557000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2012 2012-01-01 – 2012-12-31	−Unit12 11.64 million Exact value Exact value: -11636000 Unit12 2012-01-01 – 2012-12-31: -11636000 Unit12 Inspect Net Income Open source Share or cite Citation for Net Income · Aratana Therapeutics, Inc. · 2012-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Net Income: -11636000 Unit12 Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=Unit12&dimensions= Input fundies:NetIncome: -11636000 Unit12 (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919015000005/petx-20141231.xml#2296633 Filing: 000150919015000005 The citation records this snapshot. The page link may show a newer release later.	−Unit12 7.82 million Exact value Exact value: -7816000 Unit12 2012-01-01 – 2012-12-31: -7816000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aratana Therapeutics, Inc. · 2012-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Operating Cash Flow: -7816000 Unit12 Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -7816000 Unit12 (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919015000005/petx-20141231.xml#2295616 Filing: 000150919015000005 The citation records this snapshot. The page link may show a newer release later.	Unit12 10,000 Exact value Exact value: 10000 Unit12 2012-01-01 – 2012-12-31: 10000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aratana Therapeutics, Inc. · 2012-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Capital Expenditure: 10000 Unit12 Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 10000 Unit12 (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919015000005/petx-20141231.xml#2329658 Filing: 000150919015000005 The citation records this snapshot. The page link may show a newer release later.	−Unit12 7.83 million Calculation and evidence -7816000 − 10000 Unit12 Exact free cash flow: -7826000 Unit12 2012-01-01 – 2012-12-31: -7816000 Unit12 · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 10000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aratana Therapeutics, Inc. · 2012-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Free cash flow: -7826000 Unit12 Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7816000 Unit12 (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919015000005/petx-20141231.xml#2295616 Filing: 000150919015000005 Input fundies:CapitalExpenditure: 10000 Unit12 (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919015000005/petx-20141231.xml#2329658 Filing: 000150919015000005 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	−Unit12 6.94 million Exact value Exact value: -6938000 Unit12 2013-01-01 – 2013-12-31: -6938000 Unit12 Inspect Net Income Open source Share or cite Citation for Net Income · Aratana Therapeutics, Inc. · 2013-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Net Income: -6938000 Unit12 Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=Unit12&dimensions= Input fundies:NetIncome: -6938000 Unit12 (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919016000061/petx-20151231.xml#1804121 Filing: 000150919016000061 The citation records this snapshot. The page link may show a newer release later.	−Unit12 16.15 million Exact value Exact value: -16151000 Unit12 2013-01-01 – 2013-12-31: -16151000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aratana Therapeutics, Inc. · 2013-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Operating Cash Flow: -16151000 Unit12 Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -16151000 Unit12 (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919016000061/petx-20151231.xml#1803422 Filing: 000150919016000061 The citation records this snapshot. The page link may show a newer release later.	Unit12 94,000 Exact value Exact value: 94000 Unit12 2013-01-01 – 2013-12-31: 94000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aratana Therapeutics, Inc. · 2013-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Capital Expenditure: 94000 Unit12 Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 94000 Unit12 (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919016000061/petx-20151231.xml#1834156 Filing: 000150919016000061 The citation records this snapshot. The page link may show a newer release later.	−Unit12 16.25 million Calculation and evidence -16151000 − 94000 Unit12 Exact free cash flow: -16245000 Unit12 2013-01-01 – 2013-12-31: -16151000 Unit12 · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 94000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aratana Therapeutics, Inc. · 2013-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Free cash flow: -16245000 Unit12 Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -16151000 Unit12 (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919016000061/petx-20151231.xml#1803422 Filing: 000150919016000061 Input fundies:CapitalExpenditure: 94000 Unit12 (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919016000061/petx-20151231.xml#1834156 Filing: 000150919016000061 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−Unit12 38.82 million Exact value Exact value: -38816000 Unit12 2014-01-01 – 2014-12-31: -38816000 Unit12 Inspect Net Income Open source Share or cite Citation for Net Income · Aratana Therapeutics, Inc. · 2014-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Net Income: -38816000 Unit12 Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=Unit12&dimensions= Input fundies:NetIncome: -38816000 Unit12 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919017000010/petx-20161231.xml#1381664 Filing: 000150919017000010 The citation records this snapshot. The page link may show a newer release later.	−Unit12 32.19 million Exact value Exact value: -32188000 Unit12 2014-01-01 – 2014-12-31: -32188000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aratana Therapeutics, Inc. · 2014-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Operating Cash Flow: -32188000 Unit12 Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -32188000 Unit12 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919017000010/petx-20161231.xml#1380965 Filing: 000150919017000010 The citation records this snapshot. The page link may show a newer release later.	Unit12 471,000 Exact value Exact value: 471000 Unit12 2014-01-01 – 2014-12-31: 471000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aratana Therapeutics, Inc. · 2014-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Capital Expenditure: 471000 Unit12 Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 471000 Unit12 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919017000010/petx-20161231.xml#1414669 Filing: 000150919017000010 The citation records this snapshot. The page link may show a newer release later.	−Unit12 32.66 million Calculation and evidence -32188000 − 471000 Unit12 Exact free cash flow: -32659000 Unit12 2014-01-01 – 2014-12-31: -32188000 Unit12 · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 471000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aratana Therapeutics, Inc. · 2014-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Free cash flow: -32659000 Unit12 Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -32188000 Unit12 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919017000010/petx-20161231.xml#1380965 Filing: 000150919017000010 Input fundies:CapitalExpenditure: 471000 Unit12 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919017000010/petx-20161231.xml#1414669 Filing: 000150919017000010 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−Unit12 84.05 million Exact value Exact value: -84054000 Unit12 2015-01-01 – 2015-12-31: -84054000 Unit12 Inspect Net Income Open source Share or cite Citation for Net Income · Aratana Therapeutics, Inc. · 2015-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Net Income: -84054000 Unit12 Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=Unit12&dimensions= Input fundies:NetIncome: -84054000 Unit12 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919018000010/petx-20171231.xml#1305046 Filing: 000150919018000010 The citation records this snapshot. The page link may show a newer release later.	−Unit12 38.5 million Exact value Exact value: -38495000 Unit12 2015-01-01 – 2015-12-31: -38495000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aratana Therapeutics, Inc. · 2015-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Operating Cash Flow: -38495000 Unit12 Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -38495000 Unit12 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919018000010/petx-20171231.xml#1304467 Filing: 000150919018000010 The citation records this snapshot. The page link may show a newer release later.	Unit12 2.25 million Exact value Exact value: 2245000 Unit12 2015-01-01 – 2015-12-31: 2245000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aratana Therapeutics, Inc. · 2015-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Capital Expenditure: 2245000 Unit12 Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 2245000 Unit12 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919018000010/petx-20171231.xml#1332386 Filing: 000150919018000010 The citation records this snapshot. The page link may show a newer release later.	−Unit12 40.74 million Calculation and evidence -38495000 − 2245000 Unit12 Exact free cash flow: -40740000 Unit12 2015-01-01 – 2015-12-31: -38495000 Unit12 · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 2245000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aratana Therapeutics, Inc. · 2015-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Free cash flow: -40740000 Unit12 Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -38495000 Unit12 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919018000010/petx-20171231.xml#1304467 Filing: 000150919018000010 Input fundies:CapitalExpenditure: 2245000 Unit12 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919018000010/petx-20171231.xml#1332386 Filing: 000150919018000010 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−Unit12 33.58 million Exact value Exact value: -33575000 Unit12 2016-01-01 – 2016-12-31: -33575000 Unit12 Inspect Net Income Open source Share or cite Citation for Net Income · Aratana Therapeutics, Inc. · 2016-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Net Income: -33575000 Unit12 Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=Unit12&dimensions= Input fundies:NetIncome: -33575000 Unit12 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919019000018/petx-20181231.xml#1211520 Filing: 000150919019000018 The citation records this snapshot. The page link may show a newer release later.	−Unit12 11.32 million Exact value Exact value: -11323000 Unit12 2016-01-01 – 2016-12-31: -11323000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aratana Therapeutics, Inc. · 2016-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Operating Cash Flow: -11323000 Unit12 Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -11323000 Unit12 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919019000018/petx-20181231.xml#1210899 Filing: 000150919019000018 The citation records this snapshot. The page link may show a newer release later.	Unit12 72,000 Exact value Exact value: 72000 Unit12 2016-01-01 – 2016-12-31: 72000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aratana Therapeutics, Inc. · 2016-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Capital Expenditure: 72000 Unit12 Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 72000 Unit12 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919019000018/petx-20181231.xml#1236603 Filing: 000150919019000018 The citation records this snapshot. The page link may show a newer release later.	−Unit12 11.4 million Calculation and evidence -11323000 − 72000 Unit12 Exact free cash flow: -11395000 Unit12 2016-01-01 – 2016-12-31: -11323000 Unit12 · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 72000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aratana Therapeutics, Inc. · 2016-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Free cash flow: -11395000 Unit12 Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -11323000 Unit12 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919019000018/petx-20181231.xml#1210899 Filing: 000150919019000018 Input fundies:CapitalExpenditure: 72000 Unit12 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919019000018/petx-20181231.xml#1236603 Filing: 000150919019000018 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−Unit12 47.51 million Exact value Exact value: -47510000 Unit12 2017-01-01 – 2017-12-31: -47510000 Unit12 Inspect Net Income Open source Share or cite Citation for Net Income · Aratana Therapeutics, Inc. · 2017-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Net Income: -47510000 Unit12 Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=Unit12&dimensions= Input fundies:NetIncome: -47510000 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919019000018/petx-20181231.xml#1212035 Filing: 000150919019000018 The citation records this snapshot. The page link may show a newer release later.	−Unit12 38.19 million Exact value Exact value: -38185000 Unit12 2017-01-01 – 2017-12-31: -38185000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aratana Therapeutics, Inc. · 2017-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Operating Cash Flow: -38185000 Unit12 Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -38185000 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919019000018/petx-20181231.xml#1211106 Filing: 000150919019000018 The citation records this snapshot. The page link may show a newer release later.	Unit12 1,000 Exact value Exact value: 1000 Unit12 2017-01-01 – 2017-12-31: 1000 Unit12 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aratana Therapeutics, Inc. · 2017-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Capital Expenditure: 1000 Unit12 Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=Unit12&dimensions= Input fundies:CapitalExpenditure: 1000 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919019000018/petx-20181231.xml#1236806 Filing: 000150919019000018 The citation records this snapshot. The page link may show a newer release later.	−Unit12 38.19 million Calculation and evidence -38185000 − 1000 Unit12 Exact free cash flow: -38186000 Unit12 2017-01-01 – 2017-12-31: -38185000 Unit12 · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 1000 Unit12 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aratana Therapeutics, Inc. · 2017-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Free cash flow: -38186000 Unit12 Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -38185000 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919019000018/petx-20181231.xml#1211106 Filing: 000150919019000018 Input fundies:CapitalExpenditure: 1000 Unit12 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919019000018/petx-20181231.xml#1236806 Filing: 000150919019000018 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−Unit12 14.72 million Exact value Exact value: -14722000 Unit12 2018-01-01 – 2018-12-31: -14722000 Unit12 Inspect Net Income Open source Share or cite Citation for Net Income · Aratana Therapeutics, Inc. · 2018-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Net Income: -14722000 Unit12 Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=Unit12&dimensions= Input fundies:NetIncome: -14722000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919019000018/petx-20181231.xml#1213223 Filing: 000150919019000018 The citation records this snapshot. The page link may show a newer release later.	−Unit12 11.26 million Exact value Exact value: -11261000 Unit12 2018-01-01 – 2018-12-31: -11261000 Unit12 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aratana Therapeutics, Inc. · 2018-12-31 Aratana Therapeutics, Inc. (edgar:1509190) Operating Cash Flow: -11261000 Unit12 Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:33:14Z Snapshot: 5c89a215d6efd741b1911402a38feb5f33812dfdf29ad33f715e989a5f487a64 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1509190/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=Unit12&dimensions= Input fundies:OperatingCashFlow: -11261000 Unit12 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1509190/000150919019000018/petx-20181231.xml#1211313 Filing: 000150919019000018 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

113 filings · 2,551 latest values · 2,551 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001509190, 1509190, PETX, edgar:1509190, petx

Also known as ARATANA THERAPEUTICS, INC., Aratana Therapeutics, Inc.

Aratana Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2018 2018-01-01 – 2018-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation